Transition Metal Complexes with Heterocyclic Ligands for Anticancer Drug Development
Xplore Environment: An International Journal · 13.09.2021 · 1 (2) · 05-10
DOI: 10.51470/xe.2021.1.2.17 ↗Kurz gefasst
Fachartikel in der Zeitschrift Xplore Environment: An International Journal, online erschienen am 19.10.2021. Verfasst von Amit Thakur und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Transition metal complexes containing heterocyclic ligands have emerged as an important class of candidates in contemporary anticancer drug development because they combine the structural diversity of organic heterocycles with the distinctive coordination, redox, and kinetic properties of metal centers. Unlike conventional organic drugs, metal complexes can undergo ligand exchange, participate in redox reactions, interact with nucleic acids and proteins, and generate reactive oxygen species, thereby providing multiple mechanisms for disrupting cancer-cell survival. Heterocyclic ligands containing nitrogen, oxygen, sulfur, and phosphorus donor atoms can further regulate the geometry, stability, lipophilicity, cellular uptake, and biological reactivity of metal complexes. This review discusses the principles underlying the design and synthesis of transition metal complexes containing heterocyclic ligands, with emphasis on ruthenium, platinum, copper, cobalt, nickel, palladium, zinc, and iron systems. Important heterocyclic scaffolds, including pyridine, imidazole, benzimidazole, quinoline, quinazoline, thiazole, triazole, indole, and thiosemicarbazone derivatives, are examined in relation to their coordination behavior and anticancer properties. The principal mechanisms of action include DNA interaction, oxidative stress, mitochondrial dysfunction, apoptosis, cell-cycle arrest, enzyme inhibition, and interference with cancer-associated signaling pathways. Approaches for improving selectivity, aqueous stability, cellular uptake, and pharmacological performance are also discussed. Particular attention is given to structure–activity relationships, biological evaluation, resistance mechanisms, toxicity, and emerging nanotechnology-assisted delivery strategies. Overall, rational integration of metal coordination chemistry and heterocyclic medicinal chemistry provides a versatile platform for developing next-generation metallotherapeutic agents.
Zitieren
APA
Thakur, A., Thakur, S., & Thakur, A. (2021). Transition Metal Complexes with Heterocyclic Ligands for Anticancer Drug Development. Xplore Environment: An International Journal, 1(2), 05-10. https://doi.org/10.51470/xe.2021.1.2.17
Vancouver
Thakur A, Thakur S, Thakur A. Transition Metal Complexes with Heterocyclic Ligands for Anticancer Drug Development. Xplore Environment: An International Journal. 2021;1(2):05-10. doi:10.51470/xe.2021.1.2.17
BibTeX
@article{Thakur2021,
author = {Thakur, Amit and Thakur, Sarita and Thakur, Arvind},
title = {Transition Metal Complexes with Heterocyclic Ligands for Anticancer Drug Development},
journal = {Xplore Environment: An International Journal},
year = {2021},
volume = {1},
number = {2},
pages = {05--10},
doi = {10.51470/xe.2021.1.2.17}
}
EUVIMED